EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study

Louis Bessette, Jonathan Chan, Andrew Chow, Larissa Lisnevskaia, Nicolas Richard, Pierre-Andre Fournier, Dalinda Liazoghli, Tanya Girard, Derek Haaland

Rheumatology and Therapy · 2024-06 · 11 (3) · 563-582

DOI: 10.1007/s40744-024-00651-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 11.03.2024. Verfasst von Louis Bessette und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre de L'ostéoporose et de Rhumatologie de Québec (CORQ), Groupe de Recherche en Rhumatologie et Maladies Osseuses (GRMO), Université de Laval, 10…. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Upadacitinib (UPA), a selective, reversible, oral Janus kinase (JAK)-1 inhibitor, was approved in 2019 in Canada for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). This phase 4 prospective study aimed to characterise the effectiveness of UPA in the real-world population of patients with RA. METHODS: Adults with RA who initiated treatment with once daily UPA (15 mg) and enrolled in the Canadian Real-Life post-marketing Observational Study assessing the Effectiveness of UPadacitinib for treating rheumatoid arthritis (CLOSE-UP) and who completed a 6-month assessment as of 28 February 2023 were included. The primary endpoint of the CLOSE-UP study is the proportion of patients achieving a Disease Activity Score-28 Joint Count C-reactive protein (DAS28-CRP) < 2.6 at 6 months. Data was collected at routine visits. Data analysed and summarised descriptively for the overall interim population and for subgroups based on prior therapy included remission or low disease activity, patient-reported outcomes (PROs), and adverse events. RESULTS: A total of 392 patients were included in the interim analysis. Overall, 63.5% (191/301) of patients achieved a DAS28-CRP score < 2.6 at month 6, with similar rates observed for all subgroups analysed according to prior therapy including those with prior JAK inhibitor exposure (range 57.4-71.0%), and in patients who received UPA monotherapy (71.6% [48/67]). Early (month 3) and sustained improvements up to 6 months were observed for all PROs. The safety profile was consistent with previous reports. CONCLUSION: Real-world improvements in disease activity and PROs in response to UPA treatment were consistent with clinical trial data across a range of Canadian patients with prior therapy exposure and with UPA monotherapy, with an overall favourable benefit-risk profile. TRIAL REGISTRATION: NCT04574492.

Schlagwörter

Stichwörter der Autor:innen

Clinical trialJanus kinase inhibitorPhase 4Real-world effectivenessRheumatoid arthritisUpadacitinib

Autor:innen und Institutionen

  • Centre de L'ostéoporose et de Rhumatologie de Québec (CORQ), Groupe de Recherche en Rhumatologie et Maladies Osseuses (GRMO), Université de Laval, 100-1200 Avenue Germain-Des-Prés, Quebec, QC, G1V 3M7, Canada. louis.bes…
  • University of British Columbia, Vancouver, BC, Canada.
  • McMaster University, Hamilton, ON, Canada.
  • Lakeridge Health Services, Oshawa, ON, Canada.
  • Division of Rheumatology, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada.
  • AbbVie Corporation, Saint-Laurent, QC, Canada.

Förderung

  • AbbVie Canada

Zitieren

APA

Bessette, L., Chan, J., Chow, A., Lisnevskaia, L., Richard, N., Fournier, P. A., Liazoghli, D., Girard, T., & Haaland, D. (2024). Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study. Rheumatology and Therapy, 11(3), 563-582. https://doi.org/10.1007/s40744-024-00651-8

Vancouver

Bessette L, Chan J, Chow A, Lisnevskaia L, Richard N, Fournier PA, et al. Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study. Rheumatology and Therapy. 2024;11(3):563-582. doi:10.1007/s40744-024-00651-8

BibTeX
@article{Bessette2024,
  author = {Bessette, Louis and Chan, Jonathan and Chow, Andrew and Lisnevskaia, Larissa and Richard, Nicolas and Fournier, Pierre-Andre and Liazoghli, Dalinda and Girard, Tanya and Haaland, Derek},
  title = {Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study},
  journal = {Rheumatology and Therapy},
  year = {2024},
  volume = {11},
  number = {3},
  pages = {563--582},
  doi = {10.1007/s40744-024-00651-8}
}
Kostenlos starten →